14th Edition Pharma and Clinical Trials Forum

$499.00

SKU: PHP12827 Category:

Description

Report Code: PHP12827. October, 2012. Toronto

Article 1

Global Developments in Clinical Research – Implications for Canada

Dr. Judith L. Glennie
President J.L. Glennie Consulting

Article 2

Canadian Participation on Global Trials

Elise Beausoleil
Head of Clinical Research
Lundbeck Canada Inc.

Article 3

Global Developments in Clinical Research – Implications for Canada

Perry Poole, RN, BA
Director Clinical Operations North America
Hoffmann-La Roche Limited

Article 4

Pushing the Frontiers of Clinical Research in Canada

Karen Arts, OICR
Director, Business Development Clinical Trials
Ontario Institute for Cancer Research
Co-Founder and Chair of Board of Directors
Network of Networks (N2)

Heather Harris, BCCRIN
Director Operations
BC Clinical Research Infrastructure Network

Anne Tomalin
Managing Director, Strategic Regulatory and Safety
OptumInsight

Dr. Clive Ward-Able
Executive Director, R&D Amgen Canada Inc.

Article 5

Dissemination of Interim Study Results to Trial Participants – Case Study:
The REACH Study

Sandra Gazel, M.Sc., MBA
Associate Director Clinical Operation
Abbott Canada

Article 6

Sharing Clinical Research Data – Making the Case for Openness?

Karmela Krleža-Jerić, MD, M.Sc., D.Sc
Adjunct Faculty, Department of Epidemiology and
Community Medicine, University of Ottawa
Founder and Leader, Ottawa Group

Article 7

Global Trends and Their Transformational Impact on the
Drug Development Enterprise

Kenneth A. Getz, MBA
Director, Sponsored Research Programs
Tufts Centre for the Study of Drug Development

Article 8

An Action Plan to Help Attract More Clinical Trials to Canada:
To Your Health & Prosperity

Tina Saryeddine, PhD, MHA, CHE
Assistant Vice-President Research and Policy Analysis
Association of Canadian Academic Healthcare Organizations

Article 9

Privacy Developments in a Research Context

Mary Jane Dykeman
Partner
Dykeman Dewhirst O’Brien LLP

Article 10

Privacy Developments in a Changing Industry

Jason Ridderikhoff
Manager Clinical Operations
Quintiles

Article 11

Ethics Reform: Harmonizing Reviews: A Competitive Advantage?

Ronald Fehst
Institutional Review Board Services
President, Ronald Fehst Research Consultants

Article 12

R&D Credits and the Pharmaceutical Industry

Elizabeth Pringle, M.Sc.
Associate Partner, SR&ED and Business Tax Incentives
Ernst & Young LLP

Article 13

R&D Credits and the Pharmaceutical Industry

Carlos Portillo, CPA, CMA
Director of Finance R&D North America
Hoffmann-La Roche Limited

Article 14

Regulatory Roadmap for Health Products and Food

Joanne Garrah
Associate Director
Office of Legislative and Regulatory Modernization, Health Canada

Article 15

Evolving the Canadian Research Environment to Successfully
Compete with Global Pressure

Julie Stover, MBA
Mastermind of Possibilities
STIRIS Research Inc.

Article 16

Making Ontario a Preferred Location for Global Clinical Trials

Ronald J. Heslegrave, PhD
Interim Executive Director
Clinical Trials Ontario

Article 17

Business Process Improvements to Invigorate Canadian
Clinical Research: Tackling Operational Complexity

Elaine Kielo
Clinical Operations Integration Manager
North America, Latin America and AMERIT Regional Clinical Operations
Eli Lilly Canada

Article 18

Business Process Improvements to Invigorate Canadian
Clinical Research: Tackling Operational Complexity

Shantal Feltham
President and CEO
STIRIS Research Inc.

Article 19

Business Process Improvements to Invigorate Canadian
Clinical Research: Tackling Operational Complexity

J. Carter Thorne, MD, FRCP, FACP
Internal Medicine & Rheumatology
Principal Investigator, The Arthritis Program Research Group
Secretary Treasurer, Canadian Rheumatology Research Consortium

Article 20

Business Process Improvements to Invigorate Canadian
Clinical Research: Tackling Operational Complexity

Christopher R. Viney, BA, JD
Director of Legal Services
The Hospital for Sick Children

Article 21

Clinical Research Business Model Case Study: Succeeding
in a Canadian Research Environment

Ronnie Aronson, MD, FRCPC, FACE
Executive Director
LMC Diabetes & Endocrinology

Article 22

Safety Reporting and Safety Management in Clinical Trials

Kim Remnant
Manager, Patient Safety/Product Complaints
Eli Lilly Canada Inc.

J. Michelle Filice, BPHE, CCRA
Process Manager, Clinical Studies Resource Centre
Sunnybrook Health Sciences Centre

Article 23

Patent Law Developments Affecting Clinical Trials

Noel Courage
Partner
Bereskin & Parr LLP

Article 24

Promising Trends for Canada’s Clinical Research Prospects

John Akitt
President
Trial Management Group Inc.

Article 25

Promising Trends: A Site Perspective

Sharon Cohen, MD, FRCPC (neurology)
Behavioural Neurologist and Medical Director
Toronto Memory Program

Article 26

Promising Trends for Canada’s Clinical Research Prospects

Perry Poole, RN, BA
Director Clinical Operations North
Hoffmann –La Roche Limited

Article 27

Benefit-Harm-Uncertainty Management: Clinical Studies Opportunities with
a New Regulatory Oversight Framework

Robyn Lim, PhD
Senior Science Advisor
Office of Legislative and Regulatory Modernization
Health Products and Food Branch, Health Canada